PDCD1 and cancer: The development of ICP inhibitors that target coinhibitory interactions, such as CD80–CTLA4 and PD-1–PD-L1, to overcome immunological anergy and invigorate the T effector cells restoring their ability to destroy cancer cells was named “Breakthrough of the Year” in 2013 by Science magazine (4).